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1. INTRODUCTION {#rmv2112-sec-0005}
===============

During the last two decades, coronaviruses have been recognized as one of the most critical human pathogenic viruses that affect global health and cause concern in the world health system.[^1^](#rmv2112-bib-0001){ref-type="ref"} Coronavirus is classified into four genera: alpha, beta, delta, and gamma. Major human pathogenic viruses belong to the beta genus, including Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and the 2019 novel coronavirus (COVID‐19).[^2^](#rmv2112-bib-0002){ref-type="ref"}

Although coronaviruses are recognized as causes of the common cold, SARS was the first coronavirus to cause a life‐threatening respiratory infection in humans. It was endemic in Guangzhou China in 2002‐2003 and quickly spread to other countries in Asia, the Americas, Europe, and South Africa. A total of 8098 SARS infected cases and 774 deaths (about 10% mortality) were reported.[^3^](#rmv2112-bib-0003){ref-type="ref"}

About a decade later, MERS caused respiratory infection in the Middle East. Most of these patients had a history of travel to the Arabian Peninsula, or they were in contact with infected people, of which some were camel shepherds. After the Middle East, the second outbreak of MERS occurred in 2014‐2017 in South Korea, indicating the circulation of the virus and a more significant concern for the world health community. At that time, MERS was responsible for infecting 2458 people and 848 deaths (about 35% mortality).[^4^](#rmv2112-bib-0004){ref-type="ref"}

In December 2019, a cluster of Covid‐19 patients with symptoms of pneumonia complicated with acute respiratory distress syndrome (ARDS) was observed in Wuhan, China.[^5^](#rmv2112-bib-0005){ref-type="ref"}, [^6^](#rmv2112-bib-0006){ref-type="ref"} In comparison to SARS and MERS, Covid‐19 has a higher rate of spread and became a pandemic in about 4 months. The high power of this large‐scale dissemination led to the quarantine of several cities in different countries.[^7^](#rmv2112-bib-0007){ref-type="ref"} Based on the World Health Organization (WHO) 57th report on 17 March 2020; worldwide there have been 179 112 confirmed cases, with 7426 deaths (about 4% mortality).[^8^](#rmv2112-bib-0008){ref-type="ref"} There is no vaccine or targeted treatment currently available for COVID‐19 infection. Treatment is mostly supportive, although multiple experimental antiviral medications are being evaluated.[^9^](#rmv2112-bib-0009){ref-type="ref"}, [^10^](#rmv2112-bib-0010){ref-type="ref"} Thus, prevention and rapid diagnosis of infected patients are crucial. The trigger for rapid screening and treatment of COVID‐19 patients is based on clinical symptoms, laboratory, and radiographic findings that are similar to SARS and MERS infections.

In this study, we attempted to distinguish the clinical symptoms, laboratory findings, radiographic signs, and outcomes of confirmed COVID‐19, SARS, and MERS patients. All findings are compared to determine unique features among each of them. These data could be helpful in the early diagnosis and prevention of infection as well as providing more reliable epidemiological data on a large‐scale for health care policies and future studies.

2. METHODS {#rmv2112-sec-0006}
==========

2.1. Search strategy {#rmv2112-sec-0007}
--------------------

This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses Statement (PRISMA) guidelines, and it has been registered in the PROSPERO database (ID 176106).[^11^](#rmv2112-bib-0011){ref-type="ref"} We searched all studies published up to 28 February 2020, from the following databases: Embase, Scopus, PubMed, Web of Science, and the Cochrane library. Search medical subject headings (MeSH) terms used were: "COVID‐19," "Coronavirus," "Severe Acute Respiratory Syndrome," "SARS Virus," "severe acute respiratory syndrome coronavirus 2", "Coronavirus Infections," "Middle East Respiratory Syndrome Coronavirus," and all their synonyms like "Wuhan Coronavirus," "SARS‐CoV‐2," and "COVID‐19," "2019‐nCoV" and MERS. Moreover, we searched for unpublished and grey literature with Google scholar, Centre for Disease Controls (CDC) and WHO databases. We also examined references of included articles to find additional relevant studies. There was no language restriction, and all included studies were written in English or Chinese languages; the latter was translated by <https://translate.google.com/>. Additional search strategy details are provided in Table S1.

2.2. Study selection {#rmv2112-sec-0008}
--------------------

Duplicate studies were removed using EndNote X7 (Thomson Reuters, New York, NY, USA). Records were initially screened by title and abstract by independently four authors (AP, SG, AK, and RF). The full‐text of potentially eligible records was retrieved and examined, and any discrepancies were resolved by consensus.

2.3. Eligibility and inclusion criteria {#rmv2112-sec-0009}
---------------------------------------

Studies had to fulfill the following predetermined criteria to be eligible for inclusion in our meta‐analysis. All case‐control, cross‐sectional, cohort studies, case reports, and case series peer‐reviewed studies were included if they reported the number of confirmed cases of patients with demographic data, \[AND\] \[OR\] clinical data, \[AND\] \[OR\] laboratory data, \[AND\] \[OR\] risk factor data.

2.4. Exclusion criteria {#rmv2112-sec-0010}
-----------------------

Studies were excluded if they did not report the number of confirmed cases. Letters to the editor, individual case reports, review articles, and news reports were also excluded. Duplicate information from the same patient was combined and counted as a single case when the data was reported twice.

2.5. Data extraction {#rmv2112-sec-0011}
--------------------

All COVID‐19 included publications were published in 2020, and all patients were from China. The following items were extracted from each article: first author, center and study location in China, countries, sample collection time, patient follow‐up time, the reference standard for infection confirmation, number of confirmed cases, study type, and all demographic, clinical, laboratory data, and risk factor data. Three of our authors (SG, AK, and RF) independently extracted data, and all extracted data were checked randomly by another author (AP); differences were resolved by consensus.

2.6. Quality assessment {#rmv2112-sec-0012}
-----------------------

Quality assessments of studies were performed by two reviewers independently according to the Critical Appraisal Checklist recommended by the Joanna Briggs Institute,[^12^](#rmv2112-bib-0012){ref-type="ref"} and disagreements were resolved by consensus. The checklist is composed of nine questions that reviewers addressed for each study. The "Yes" answer to each question received one point. Thus, the final scores for each study could range from zero to nine (Table S2).

2.7. Analysis {#rmv2112-sec-0013}
-------------

Data cleaning and preparation were done in Microsoft Excel 2010 (Microsoft©, Redmond, WA, USA), and further analyses were carried out via Comprehensive Meta‐Analysis Software Version 2.0 (Biostat, Englewood, NJ). Determination of heterogeneity among the studies was undertaken using the chi‐squared test (Cochran\'s Q) to assess the appropriateness of pooling data. Depending on the heterogeneity test, we used either random or fixed‐effect models for pooled results. In the case of high heterogeneity (I2 \> 50%), a random effect model (M‐H heterogeneity) was applied, while in low heterogeneity cases (I2 \< 50%), a fixed‐effect model was used.[^13^](#rmv2112-bib-0013){ref-type="ref"} Percentages and means ± SDs were calculated to describe the distributions of categorical and continuous variables, respectively. *P* values reflect study heterogeneity with \<.05 being significant. We also used the funnel plot, Begg\'s, and Egger\'s tests based on the symmetry assumption to detect publication bias (Figure [S1](#rmv2112-supitem-0001){ref-type="supplementary-material"}).

3. RESULTS {#rmv2112-sec-0014}
==========

3.1. Characteristics of included studies {#rmv2112-sec-0015}
----------------------------------------

The process of study selection is displayed in Figure [1](#rmv2112-fig-0001){ref-type="fig"}. A total of 36 115 reports were screened for the analysis of patients with COVID‐19, 36 014 were excluded after the title, and abstract screening and the full text of 81 reports were reviewed in full text. We excluded studies that did not report sufficient data. Out of 114 included studies, 20 studies met the inclusion criteria for COVID‐19, 51 for SARS, 43 for MERS. The characteristics of the selected articles are summarized in Table [1](#rmv2112-tbl-0001){ref-type="table"}. Of the 20 COVID‐19 studies that were included in the analysis, 19 studies were in English, and one was in Chinese.[^21^](#rmv2112-bib-0021){ref-type="ref"} All COVID‐19 studies were retrospective, published in 2020, and all patients were from China.

![Flow diagram of literature search and study selection (PRISMA flow chart)](RMV-9999-e2112-g001){#rmv2112-fig-0001}

###### 

Characterization of included studies

                                                                         COVID‐19 studies (Total of 20 studies, 52 251 patients)                                                                                                                                                                                       
  ---------------------------------------------------------------------- --------------------------------------------------------- ------------------------------- -------------------- -------------------- -------------------------- ----------------------------- ------------------ ----------------------------- -----------------------------
  Nanshan Chen [^14^](#rmv2112-bib-0014){ref-type="ref"}                 Wuhan Jinyintan Hospital                                  1 Jan to 20 Jan 2020            2020                 5‐24                 99                         55·5 (21‐82)                  67                 RT‐PCR                        Retrospective
  Kaiyuan Sun [^15^](#rmv2112-bib-0015){ref-type="ref"}                  Multicenter                                               20 Jan‐Jan 29, 2020             2020                 42                   288                        49 (2‐89)                     62.3               CDC guideline                 Retrospective
  Jie Li [^16^](#rmv2112-bib-0016){ref-type="ref"}                       Dazhou Central Hospital                                   22 January‐10 February 2020     2020                 1‐21                 17                         45.1 (32‐65)                  9                  RT‐PCR                        Retrospective
  Dawei Wang [^17^](#rmv2112-bib-0017){ref-type="ref"}                   Zhongnan Hospital of Wuhan                                1 January‐28 January 2020       2020                 6‐34                 138                        56 (42‐68)                    75                 RT‐PCR                        Retrospective
  Chaolin Huang [^18^](#rmv2112-bib-0018){ref-type="ref"}                Jin Yintan Hospital (Wuhan)                               31 Dec 2019‐UN                  2020                 NA                   41                         49 (41‐58)                    30                 RT‐PCR                        Retrospective
  Weijie Guan[^19^](#rmv2112-bib-0019){ref-type="ref"}                   Multicenter                                               NA                              2020                 NA                   1099                       47 (35‐58)                    640                RT‐PCR                        Retrospective
  Yang Yang[^20^](#rmv2112-bib-0020){ref-type="ref"}                     NA                                                        NA                              2020                 51 d                 4021                       49                            2211               NA                            Retrospective
  Lei Chen (Chinese)[^21^](#rmv2112-bib-0021){ref-type="ref"}            Tongji hospital in Wuhan                                  14‐29 January 2020              2020                 15 d                 29                         56 (26‐79)                    21                 RT‐PCR                        Retrospective
  Adam Bernheim[^22^](#rmv2112-bib-0022){ref-type="ref"}                 Multicenter                                               18 January‐2 February 2020      2020                 12 d                 121                        45 (18‐80)                    61                 RT‐PCR & CT scan              retrospective
  Feng Pan[^23^](#rmv2112-bib-0023){ref-type="ref"}                      Union Hospital                                            12 Jan‐6 Feb 2020               2020                 NA                   21                         40 (25‐63)                    15                 RT‐PCR                        Retrospective
  Jin Zhang[^24^](#rmv2112-bib-0024){ref-type="ref"}                     No.7 hospital of Wuhan                                    16th Jan to 3rd Feb 2020        2020                 NA                   140                        57 (25‐87)                    71                 RT‐PCR                        Retrospective
  Yichun Cheng[^25^](#rmv2112-bib-0025){ref-type="ref"}                  Tongji hospital in Wuhan                                  28 January‐11 February 2020     2020                 10 (7‐13)            710                        63 (51‐71)                    374                RT‐PCR                        Retrospective
  Ming‐Yen[^26^](#rmv2112-bib-0026){ref-type="ref"}                      Hong Kong‐Shenzhen Hospital                               NA                              2020                 NA                   21                         56 (37‐65)                    13                 RT‐PCR                        Retrospective
  Sijia Tian[^27^](#rmv2112-bib-0027){ref-type="ref"}                    Beijing Emergency Medical Service                         20 Jan to 10 Feb 2020           2020                 Feb. 10 20           262                        47.5 (1‐94)                   127                RT‐PCR                        Retrospective
  Qun Li[^28^](#rmv2112-bib-0028){ref-type="ref"}                        NA                                                        NA                              2020                 NA                   425                        15‐89 (26‐82)                 240                WHO guideline                 Retrospective
  De Chang[^29^](#rmv2112-bib-0029){ref-type="ref"}                      Three hospitals in Beijing                                16 January‐29 January 2020      2020                 4 Feb. 2020          13                         34 (34‐48)                    10                 NA                            Retrospective
  Xiao‐Wei Xu[^30^](#rmv2112-bib-0030){ref-type="ref"}                   Zhejiang province                                         10 January‐26 January 2020      2020                 10 d                 62                         41 (32‐52)                    36                 WHO guideline                 Retrospective
  Fengxiang Song[^31^](#rmv2112-bib-0031){ref-type="ref"}                Center for Disease Control, Shanghai                      20 January‐27 January 2020      2020                 NA                   51                         49 (16‐76)                    25                 CT scan & nucleic acid test   Retrospective
  Michael Chung[^32^](#rmv2112-bib-0032){ref-type="ref"}                 Multicenter                                               18‐27 January 2020              2020                 NA                   21                         51 (29‐77)                    13                 CT scan, NA                   Retrospective
  Zunyou Wu (CDC)[^33^](#rmv2112-bib-0033){ref-type="ref"}               Multicenter                                               through 11 February 2020        2020                 15 d                 44 672                     30‐79                         22 981             nucleic acid test result      Retrospective
                                                                         **SARS studies (Total of 51 studies, 10 037 patients)**                                                                                                                                                                                       
  **First author**                                                       **Sampling center/Country**                               **Sample collection time**      **Published year**   **Patient follow**   **N confirmed patients**   **Mean age in years (IQR)**   **N sex (male)**   **Reference standard**        **Study type**
  Ali S. Omrani[^34^](#rmv2112-bib-0034){ref-type="ref"}                 Saudi Arabia                                              2013                            2013                 NA                   3                          UN                            UN                 RT‐PCR                        Case series
  Owen Tak‐Yin Tsang[^35^](#rmv2112-bib-0035){ref-type="ref"}            Hong Kong                                                 26 January 2003‐31 March 2003   2003                 NA                   156                        UN                            90                 RT‐PCR                        Retrospective
  Li‐Yang Hsu[^36^](#rmv2112-bib-0036){ref-type="ref"}                   Singapore                                                 2003                            2003                 NA                   20                         (19‐73)                       5                  RT‐PCR                        Retrospective
  Christl A Donnelly[^37^](#rmv2112-bib-0037){ref-type="ref"}            Hong Kong                                                 2003                            2003                 NA                   1425                       UN                            UN                 RT‐PCR                        Prospective
  Christopher[^38^](#rmv2112-bib-0038){ref-type="ref"}                   Canada                                                    2003                            2003                 NA                   144                        (34‐57)                       NA                 RT‐PCR                        Retrospective
  Monali Varia[^39^](#rmv2112-bib-0039){ref-type="ref"}                  Canada                                                    2003                            2003                 NA                   128                        42 (21 m‐86 y)                51                 RT‐PCR                        Retrospective
  Robert A Fowler[^40^](#rmv2112-bib-0040){ref-type="ref"}               Canada                                                    2003                            2003                 NA                   38                         (39‐69.6)                     23                 RT‐PCR                        Retrospective
  J S M Peiris[^41^](#rmv2112-bib-0041){ref-type="ref"}                  China                                                     2003                            2003                 NA                   50                         (23‐74)                       NA                 RT‐PCR                        prospective
  J S M Peiris[^42^](#rmv2112-bib-0042){ref-type="ref"}                  Hong Kong                                                 2003                            2003                 NA                   75                         UN                            36                 RT‐PCR                        Prospective
  J W M Chan[^43^](#rmv2112-bib-0043){ref-type="ref"}                    Hong Kong                                                 2003                            2003                 NA                   115                        UN                            NA                 RT‐PCR                        Retrospective
  Jann‐Tay Wang[^44^](#rmv2112-bib-0044){ref-type="ref"}                 Taiwan                                                    2003                            2003                 NA                   76                         46.5 (24‐87)                  34                 RT‐PCR                        Retrospective
  K L E Hon[^45^](#rmv2112-bib-0045){ref-type="ref"}                     China                                                     2003                            2003                 NA                   10                         NA                            2                  RT‐PCR                        Retrospective
  K. T. Wong[^46^](#rmv2112-bib-0046){ref-type="ref"}                    Hong Kong                                                 2003                            2003                 NA                   138                        39 (20‐83)                    66                 RT‐PCR                        Retrospective
  Kamaljit Singh[^47^](#rmv2112-bib-0047){ref-type="ref"}                Singapore                                                 2003                            2003                 NA                   14                         58 (21‐84)                    5                  CT scan and RT‐PCR            Retrospective
  Kenneth W. Tsang[^48^](#rmv2112-bib-0048){ref-type="ref"}              China                                                     2003                            2003                 NA                   10                         52.5 ± 11                     5                  RT‐PCR                        Retrospective
  Marianna Ofner‐Agostini[^49^](#rmv2112-bib-0049){ref-type="ref"}       Canada                                                    2003                            2006                 NA                   17                         39.2 (27‐58)                  4                  RT‐PCR                        Retrospective
  N S Zhong[^50^](#rmv2112-bib-0050){ref-type="ref"}                     China                                                     2002                            2003                 NA                   50                         38.4                          28                 RT‐PCR                        Retrospective
  Nelson Lee[^51^](#rmv2112-bib-0051){ref-type="ref"}                    China                                                     2003                            2004                 NA                   17                         34 (22‐57)                    6                  RT‐PCR                        Retrospective
  Nelson Lee[^52^](#rmv2112-bib-0052){ref-type="ref"}                    China                                                     2003                            2003                 NA                   138                        NA                            NA                 RT‐PCR                        Cohort
  P.L. Ho[^53^](#rmv2112-bib-0053){ref-type="ref"}                       China                                                     2003                            2005                 NA                   44                         39.27 ± 11.26                 22                 RT‐PCR                        Retrospective
  Ping Tim Tsui[^54^](#rmv2112-bib-0054){ref-type="ref"}                 China                                                     2003                            2003                 NA                   323                        41 ± 14 (18‐83)               NA                 RT‐PCR                        Retrospective
  Raymond S M Wong[^55^](#rmv2112-bib-0055){ref-type="ref"}              China                                                     2003                            2003                 NA                   157                        NA                            64                 RT‐PCR                        Retrospective
  Thomas W[^56^](#rmv2112-bib-0056){ref-type="ref"}                      Singapore                                                 2003                            2003                 NA                   199                        NA                            65                 RT‐PCR                        Cohort
  Timothy H Rainer[^57^](#rmv2112-bib-0057){ref-type="ref"}              China                                                     2003                            2003                 NA                   97                         37.0 ± 15.4                   37                 RT‐PCR                        Prospective
  W.N. Wong[^58^](#rmv2112-bib-0058){ref-type="ref"}                     Hong Kong                                                 2003                            2003                 NA                   205                        35.9 ± 16.2                   90                 RT‐PCR                        Cohort
  Z. Zhao[^59^](#rmv2112-bib-0059){ref-type="ref"}                       China                                                     2002                            2003                 NA                   190                        NA                            NA                 RT‐PCR                        Prospective
  Susan M. Poutanen[^60^](#rmv2112-bib-0060){ref-type="ref"}             Canada                                                    2003                            2005                 NA                   10                         NA                            NA                 RT‐PCR                        Retrospective
  I.F.N. Hung[^61^](#rmv2112-bib-0061){ref-type="ref"}                   China                                                     2004                            2004                 NA                   154                        41.5 (20‐80)                  92                 RT‐PCR                        Retrospective
  Hoang Thu Vu[^62^](#rmv2112-bib-0062){ref-type="ref"}                  Vietnam                                                   2003                            2004                 NA                   62                         NA                            NA                 RT‐PCR                        Retrospective
  F. Chena[^63^](#rmv2112-bib-0063){ref-type="ref"}                      Hong Kong                                                 2002                            2004                 NA                   10                         NA                            5                  RT‐PCR                        Retrospective
  C.W. Leung[^64^](#rmv2112-bib-0064){ref-type="ref"}                    China                                                     2004                            2004                 NA                   64                         11.7                          29                 RT‐PCR                        Retrospective
  Monica Avendano[^65^](#rmv2112-bib-0065){ref-type="ref"}               Canada                                                    2003                            2003                 NA                   14                         42 ± 9 (27‐63)                3                  RT‐PCR                        Retrospective
  Padmini Srikantiah[^66^](#rmv2112-bib-0066){ref-type="ref"}            Us                                                        2003                            2005                 NA                   8                          NA                            NA                 RT‐PCR                        Retrospective
  Kwok H. Chan[^67^](#rmv2112-bib-0067){ref-type="ref"}                  Hong Kong                                                 2004                            2004                 NA                   322                        NA                            NA                 RT‐PCR                        Cohort
  Wannian Liang[^68^](#rmv2112-bib-0068){ref-type="ref"}                 China                                                     2003                            2003                 NA                   2443                       33 (1.0‐90)                   NA                 RT‐PCR                        Prospective
  Xinchun Chen[^69^](#rmv2112-bib-0069){ref-type="ref"}                  China                                                     2004                            2004                 NA                   36                         30.39 ± 12.15                 20                 RT‐PCR                        Retrospective
  Chi‐wai Leung[^70^](#rmv2112-bib-0070){ref-type="ref"}                 Hong Kong                                                 2004                            2004                 NA                   44                         12 (17‐50)                    20                 RT‐PCR                        Prospective
  LCL Heung[^71^](#rmv2112-bib-0071){ref-type="ref"}                     Hong Kong                                                 2006                            2006                 NA                   93                         NA                            18                 IF                            Cross‐sectional
  Ming‐Han Tsai[^72^](#rmv2112-bib-0072){ref-type="ref"}                 Taiwan.                                                   2003                            2008                 NA                   124                        NA                            NA                 ELISA                         Retrospective
  Hy A. Dwosh[^73^](#rmv2112-bib-0073){ref-type="ref"}                   Us                                                        2003                            2003                 NA                   16                         (24‐80)                       4                  RT‐PCR                        Retrospective
  Ari Bitnun[^73^](#rmv2112-bib-0073){ref-type="ref"}                    Canada                                                    2003                            2003                 NA                   15                         NA                            6                  RT‐PCR                        Prospective
  Alice S. Ho[^74^](#rmv2112-bib-0074){ref-type="ref"}                   Hong Kong                                                 2003                            2003                 NA                   40                         (24‐50)                       9                  RT‐PCR                        Retrospective
  Leonard Grinblat[^75^](#rmv2112-bib-0075){ref-type="ref"}              Canada                                                    2003                            2003                 NA                   40                         42.7 ± 13.5 (17‐73)           18                 RT‐PCR                        Retrospective
  Cheng‐Kuo Fan[^76^](#rmv2112-bib-0076){ref-type="ref"}                 Taiwan                                                    2005                            2005                 NA                   43                         41.0 ± 17.1                   22                 RT‐PCR                        Descriptive
  Kin Wing Choi[^77^](#rmv2112-bib-0077){ref-type="ref"}                 Hong Kong                                                 2003                            2003                 NA                   227                        39 (18‐96)                    75                 RT‐PCR                        Retrospective
  GM Leung[^78^](#rmv2112-bib-0078){ref-type="ref"}                      Hong Kong                                                 2003                            2003                 NA                   1755                       NA                            777                RT‐PCR                        Retrospective
  Chung‐Ming Chu[^79^](#rmv2112-bib-0079){ref-type="ref"}                China                                                     2005                            2005                 NA                   79                         39.4 ± 11.5 (20‐72)           38                 RT‐PCR                        Retrospective
  Kwok Hong Chu[^80^](#rmv2112-bib-0080){ref-type="ref"}                 Hong Kong                                                 2004                            2004                 NA                   536                        NA                            NA                 RT‐PCR                        Retrospective
  T.‐N. Jang[^81^](#rmv2112-bib-0081){ref-type="ref"}                    Taiwan                                                    2003                            2004                 NA                   29                         42.9 (22‐82)                  9                  RT‐PCR                        Retrospective
  Tze‐wai Wong[^82^](#rmv2112-bib-0082){ref-type="ref"}                  China                                                     2004                            2004                 NA                   16                         22.3                          8                  RT‐PCR                        Retrospective
  Wei‐Kung Wang[^83^](#rmv2112-bib-0083){ref-type="ref"}                 Taiwan                                                    2003                            2004                 NA                   17                         21‐54                         9                  RT‐PCR                        Retrospective
                                                                         **MERS studies (Total 43 studies, 8, 139 patients)**                                                                                                                                                                                          
  **First author**                                                       **Sampling center/Country**                               **Sample collection time**      **Published year**   **Patient follow**   **N Confirmed patients**   **Mean age in years (IQR)**   **N Sex (male)**   **Reference standard**        **Study type**
  Asad S. Aburizaiza[^84^](#rmv2112-bib-0084){ref-type="ref"}            Saudi Arabia                                              2012                            2012                 NA                   8                          (16‐62)                       NA                 IFA                           Cross‐sectional
  Marcel A Müller[^85^](#rmv2112-bib-0085){ref-type="ref"}               Saudi Arabia                                              2012‐2013                       2015                 NA                   15                         37·13 ± 8·64 (15‐62)          NA                 ELISA, IFA                    Cross‐sectional
  Abdulkarim Alhetheel[^86^](#rmv2112-bib-0086){ref-type="ref"}          Saudi Arabia                                              2016                            2017                 NA                   30                         NA                            NA                 RT‐PCR                        Cross‐sectional
  Abdulaziz A. Bin Saeed[^87^](#rmv2112-bib-0087){ref-type="ref"}        Saudi Arabia                                              2015                            2016                 NA                   384                        (1‐66)                        226                NA                            Cross‐sectional
  Boyeong Ryu[^88^](#rmv2112-bib-0088){ref-type="ref"}                   South Korea                                               2015                            2015                 NA                   34                         (34‐56.7)                     20                 RT‐PCR                        Cross‐sectional
  Jamal Ahmadzadeh[^89^](#rmv2112-bib-0089){ref-type="ref"}              Iran                                                      2019                            2019                 NA                   107                        50 ± 17                       80                 NA                            Cross‐sectional
  Kazhal Mobaraki[^90^](#rmv2112-bib-0090){ref-type="ref"}               Iran                                                      2019                            2019                 NA                   229                        NA                            171                RT‐PCR                        Epidemiological analysis
  Abdullah Assiri[^91^](#rmv2112-bib-0091){ref-type="ref"}               Saudi Arabia                                              2013                            2013                 NA                   47                         55                            36                 RT‐PCR                        Retrospective
  Korea Centers for Disease[^92^](#rmv2112-bib-0092){ref-type="ref"}     South Korea                                               2015                            2015                 NA                   186                        55 (42‐66)                    111                RT‐PCR                        Retrospective
  Abdullah Assiri[^93^](#rmv2112-bib-0093){ref-type="ref"}               Saudi Arabia                                              2013                            2013                 NA                   23                         56 (24‐94)                    17                 RT‐PCR                        Retrospective
  Abdullah Assiri[^94^](#rmv2112-bib-0094){ref-type="ref"}               Saudi Arabia                                              2014                            2016                 NA                   38                         51 (17‐84)                    28                 RT‐PCR                        Retrospective
  Abdullah M. Assiri[^95^](#rmv2112-bib-0095){ref-type="ref"}            Saudi Arabia                                              2015                            2016                 NA                   143                        58 (2.0‐99)                   91                 RT‐PCR                        Retrospective
  Ashraf Abdel Halim[^96^](#rmv2112-bib-0096){ref-type="ref"}            Egypt                                                     2015                            2016                 NA                   32                         43.99 ± 13.03                 20                 RT‐PCR                        Retrospective
  Deborah L. Hastings[^97^](#rmv2112-bib-0097){ref-type="ref"}           Saudi Arabia                                              2014                            2016                 NA                   78                         53                            59                 RT‐PCR                        Retrospective cohort
  F S Alhamlan[^98^](#rmv2112-bib-0098){ref-type="ref"}                  Saudi Arabia                                              2012‐2015                       2016                 NA                   1275                       50 (0‐109)                    807/1246           RT‐PCR                        Retrospective
  H.E. El Bushra[^99^](#rmv2112-bib-0099){ref-type="ref"}                Saudi Arabia                                              2015                            2016                 NA                   52                         NA                            31                 RT‐PCR                        Retrospective
  Hanan H. Balkhy[^99^](#rmv2112-bib-0099){ref-type="ref"}               Saudi Arabia                                              2016                            2016                 NA                   130                        56.3                          66                 RT‐PCR                        Retrospective
  Ikwo K. Oboho[^100^](#rmv2112-bib-0100){ref-type="ref"}                Saudi Arabia                                              2014                            2015                 NA                   255                        45 (30‐59)                    174                RT‐PCR                        Retrospective
  Kyung Min Kim[^101^](#rmv2112-bib-0101){ref-type="ref"}                South Korea                                               2015                            2015                 NA                   36                         51                            20/36              RT‐PCR                        Retrospective
  Ziad A. Memish[^102^](#rmv2112-bib-0102){ref-type="ref"}               Saudi Arabia                                              2013                            2013                 NA                   7                          (29‐59)                       0                  RT‐PCR                        Retrospective
  Won Suk Choi[^103^](#rmv2112-bib-0103){ref-type="ref"}                 South Korea                                               2015                            2015                 NA                   186                        5 (16‐86)                     111                RT‐PCR                        Retrospective observational
  Mohammad Mousa Al‐Abdallat[^104^](#rmv2112-bib-0104){ref-type="ref"}   Jordon                                                    2012                            2014                 NA                   9                          40 (25‐60)                    6                  RT‐PCR                        Retrospective
  Mustafa Saad[^105^](#rmv2112-bib-0105){ref-type="ref"}                 Saudi Arabia                                              2012‐2014                       2014                 NA                   70                         62 (1‐90)                     46                 RT‐PCR                        Retrospective
  Yaseen M. Arabi[^106^](#rmv2112-bib-0106){ref-type="ref"}              Saudi Arabia                                              2012‐2013                       2014                 NA                   12                         59 (36‐83)                    8                  RT‐PCR                        Case series
  Maimuna S. Majumder[^107^](#rmv2112-bib-0107){ref-type="ref"}          South Korea                                               2015                            2015                 NA                   159                        55 ± 15.9 (16‐87)             94                 RT‐PCR                        Retrospective
  Victor Virlogeux[^108^](#rmv2112-bib-0108){ref-type="ref"}             South Korea                                               2015                            2016                 NA                   107                        54.6                          96                 NA                            Retrospective
  Jaffar A. Al‐Tawfiq[^109^](#rmv2112-bib-0109){ref-type="ref"}          Saudi Arabia                                                                                                   NA                   17                         60.7                          11                 RT‐PCR                        Case‐control
  Thamer H. Alenazi[^110^](#rmv2112-bib-0110){ref-type="ref"}            Saudi Arabia                                              2015                            2017                 NA                   130                        56.5                          66                 RT‐PCR                        Prospective
  Abdullah J. Alsahafi[^111^](#rmv2112-bib-0111){ref-type="ref"}         Saudi Arabia                                              2012‐2015                                            NA                   939                        NA                            624                NA                            
  Karuna M. Das[^112^](#rmv2112-bib-0112){ref-type="ref"}                Saudi Arabia                                              2015                            2015                 NA                   55                         54 ± 16 (12 to 85)            16                 RT‐PCR                        Retrospective
  Anwar E. Ahmed[^113^](#rmv2112-bib-0113){ref-type="ref"}               Saudi Arabia                                              2014‐2016                       2017                 NA                   660                        53.9 ± 17.9 (2‐109)           452                NA                            Retrospective
  Anwar E. Ahmed[^114^](#rmv2112-bib-0114){ref-type="ref"}               WHO website                                               2015‐2017                       2017                 NA                   537                        55 ± 17.9 (2‐109)             370                NA                            Retrospective
  Basem M. Alraddadi[^115^](#rmv2112-bib-0115){ref-type="ref"}           Saudi Arabia                                              2014                            2014                 NA                   535                        49                            518                NA                            Retrospective
  Benjamin J Cowling[^116^](#rmv2112-bib-0116){ref-type="ref"}           South Korea                                               2015                            2015                 NA                   166                        56                            101                NA                            Retrospective
  Chang Kyung Kang[^117^](#rmv2112-bib-0117){ref-type="ref"}             South Korea                                               2015                            2017                 NA                   186                        54                            111                RT‐PCR                        Retrospective
  Christian Drosten[^118^](#rmv2112-bib-0118){ref-type="ref"}            Saudi Arabia                                              2014                            2014                 NA                   12                         (3‐74)                        7                  PRNT and RT‐PCR               Cross‐sectional
  Daniel R. Feikin[^119^](#rmv2112-bib-0119){ref-type="ref"}             Saudi Arabia                                              2014                            2015                 NA                   102                        NA                            76                 NA                            retrospective
  Hamzah A. Mohd[^120^](#rmv2112-bib-0120){ref-type="ref"}               Saudi Arabia                                              2014‐2015                       2016                 NA                   80                         40                            48                 RT‐PCR                        Cohort
  Jung Wan Park[^121^](#rmv2112-bib-0121){ref-type="ref"}                South Korea                                               2015                            2017                 NA                   26                         71 (38‐86)                    13                 RT‐PCR                        Retrospective
  Nahid Sherbini[^122^](#rmv2112-bib-0122){ref-type="ref"}               Saudi Arabia                                              2014                            2016                 NA                   29                         45 ± 12                       20                 RT‐PCR                        Retrospective
  Oyelola A. Adegboye[^123^](#rmv2112-bib-0123){ref-type="ref"}          Saudi Arabia                                              2012‐2015                       2017                 NA                   959                        NA                            642                NA                            
  Ghaleb A. Almekhlafi[^124^](#rmv2112-bib-0124){ref-type="ref"}         Saudi Arabia                                                                                                   NA                   31                         59 ± 20                       22                 RT‐PCR                        Retrospective cohort
  Sun Hee Park[^125^](#rmv2112-bib-0125){ref-type="ref"}                 South Korea                                                                                                    NA                   23                         NA                            13                 RT‐PCR                        Retrospective

Abbreviations: CDC, Centers for Disease Control and Prevention; CT scan, CT scan of chest; IQR, interquartile range; N, number; NA, not known; RT‐PCR, real‐time polymerase chain reaction; WHO, World Health Organization.

3.2. Quality assessment {#rmv2112-sec-0016}
-----------------------

Quality assessment of included studies was performed based on the Critical Appraisal Checklist, and the final quality scores of the included studies are represented in Table S2. In brief, studies by Chen et al,[^14^](#rmv2112-bib-0014){ref-type="ref"} Wang et al,[^17^](#rmv2112-bib-0017){ref-type="ref"} Huang et al,[^18^](#rmv2112-bib-0018){ref-type="ref"} Guan et al,[^19^](#rmv2112-bib-0019){ref-type="ref"} Zhang et al,[^24^](#rmv2112-bib-0024){ref-type="ref"} Cheng et al,[^25^](#rmv2112-bib-0025){ref-type="ref"} Li et al,[^28^](#rmv2112-bib-0028){ref-type="ref"} Xu et al,[^30^](#rmv2112-bib-0030){ref-type="ref"} and Song et al[^31^](#rmv2112-bib-0031){ref-type="ref"} had the highest quality of the COVID‐19 studies available in the purpose of this study.

3.3. Demographics, baseline characteristics, and clinical characterization {#rmv2112-sec-0017}
--------------------------------------------------------------------------

Overall, 52 251 confirmed patients with COVID‐19 infection, 10 037 with SARS, and 8139 with MERS were included in the meta‐analysis, of which 53.7% (95% CI 50‐56.8, *P* \< .001) of COVID‐19, 43% (95% CI 40‐46.5, *P* \< .001) of SARS, 66% (95% CI 63‐69, *P* \< .001), of MERS included patients were male. Funnel plots for included studies did not detect significant publication bias (Figure [S1](#rmv2112-supitem-0001){ref-type="supplementary-material"}). Table [2](#rmv2112-tbl-0002){ref-type="table"} shows that most COVID‐19 85.6% (95% CI 73‐93, *P* \< .001), SARS 96% (95% CI 93‐97.6, *P* \< .001), and MERS 74% (95% CI 63.5‐83.5, *P* \< .001) had a fever (Figure S2). Cough was the second most common symptom presenting in COVID‐19 63% (95% CI 55.5‐70, *P* \< .001), SARS 54.2% (95% CI 49‐59, *P* \< .001), and MERS 61% (95% CI 51‐70, *P* \< .001) of patients (Figure S3**).**

###### 

Demographics, baseline characteristics, and clinical outcomes of patients with confirmed COVID‐19

<table><thead><tr class="header"><th style="text-align: left;"></th><th style="text-align: left;">COVID‐19 (Total of 20 Studies, 52, 251 Patients)</th><th style="text-align: left;">SARS (Total of 51 Studies, 10, 037 Patients)</th><th style="text-align: left;">MERS (Total 43 Studies, 8, 139 Patients)</th><th style="text-align: left;"></th><th style="text-align: left;"></th><th style="text-align: left;"></th><th style="text-align: left;"></th><th style="text-align: left;"></th><th style="text-align: left;"></th><th style="text-align: left;"></th></tr></thead><tbody><tr class="odd"><td style="text-align: left;">Age, y</td><td style="text-align: left;"><p>49.5 (mean)</p><p>(46‐52.5)</p></td><td style="text-align: left;">20</td><td style="text-align: left;">52 251</td><td style="text-align: left;"><p>37.5</p><p>(34.5‐40.5)</p></td><td style="text-align: left;">24</td><td style="text-align: left;">4309</td><td style="text-align: left;"><p>52</p><p>(51‐54.5)</p></td><td style="text-align: left;">30</td><td style="text-align: left;">5174</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Sex (Male)</td><td style="text-align: left;"><p>53.7</p><p>(50‐56.8)</p></td><td style="text-align: left;">20</td><td style="text-align: left;">52 248</td><td style="text-align: left;"><p>43 (%)</p><p>(40‐46.5)</p></td><td style="text-align: left;">35</td><td style="text-align: left;">6254</td><td style="text-align: left;"><p>66</p><p>(63‐69)</p></td><td style="text-align: left;">40</td><td style="text-align: left;">8086</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Fever</td><td style="text-align: left;"><p>85.6</p><p>(73‐93)</p></td><td style="text-align: left;">15</td><td style="text-align: left;">2832</td><td style="text-align: left;"><p>96</p><p>(93‐97.6)</p></td><td style="text-align: left;">34</td><td style="text-align: left;">6194</td><td style="text-align: left;"><p>74</p><p>(63.5‐83.5)</p></td><td style="text-align: left;">22</td><td style="text-align: left;">1583</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Cough</td><td style="text-align: left;"><p>63</p><p>(55.5‐70)</p></td><td style="text-align: left;">15</td><td style="text-align: left;">2135</td><td style="text-align: left;"><p>54.2</p><p>(49‐59)</p></td><td style="text-align: left;">32</td><td style="text-align: left;">5904</td><td style="text-align: left;"><p>61</p><p>(51‐70)</p></td><td style="text-align: left;">21</td><td style="text-align: left;">1453</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Fatigue</td><td style="text-align: left;"><p>40.3</p><p>(29‐52.5)</p></td><td style="text-align: left;">11</td><td style="text-align: left;">1959</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;"><p>28</p><p>(21‐35)</p></td><td style="text-align: left;">6</td><td style="text-align: left;">516</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Sputum production/Expectoration</td><td style="text-align: left;"><p>28</p><p>(19‐39)</p></td><td style="text-align: left;">7</td><td style="text-align: left;">1378</td><td style="text-align: left;"><p>21</p><p>(16‐27)</p></td><td style="text-align: left;">11</td><td style="text-align: left;">2320</td><td style="text-align: left;"><p>31.5</p><p>(22‐43)</p></td><td style="text-align: left;">9</td><td style="text-align: left;">757</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Myalgia</td><td style="text-align: left;"><p>26</p><p>(14‐43)</p></td><td style="text-align: left;">6</td><td style="text-align: left;">1350</td><td style="text-align: left;"><p>49.5</p><p>(44.5‐55)</p></td><td style="text-align: left;">22</td><td style="text-align: left;">2872</td><td style="text-align: left;"><p>33.3</p><p>(26.5‐41)</p></td><td style="text-align: left;">10</td><td style="text-align: left;">785</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Dyspnea</td><td style="text-align: left;"><p>20</p><p>(12.6‐32)</p></td><td style="text-align: left;">7</td><td style="text-align: left;">1730</td><td style="text-align: left;"><p>32</p><p>(20.5‐45.5)</p></td><td style="text-align: left;">18</td><td style="text-align: left;">2412</td><td style="text-align: left;"><p>40</p><p>(23‐57)</p></td><td style="text-align: left;">11</td><td style="text-align: left;">777</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Shortness of breath</td><td style="text-align: left;"><p>17</p><p>(9‐31.5)</p></td><td style="text-align: left;">3</td><td style="text-align: left;">1260</td><td style="text-align: left;"><p>32</p><p>(20‐46)</p></td><td style="text-align: left;">11</td><td style="text-align: left;">2335</td><td style="text-align: left;"><p>51</p><p>(41‐63)</p></td><td style="text-align: left;">9</td><td style="text-align: left;">695</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Chill</td><td style="text-align: left;"><p>17</p><p>(6.5‐38)</p></td><td style="text-align: left;">2</td><td style="text-align: left;">1120</td><td style="text-align: left;"><p>57.5</p><p>(50‐64)</p></td><td style="text-align: left;">21</td><td style="text-align: left;">2767</td><td style="text-align: left;"><p>41</p><p>(16‐72)</p></td><td style="text-align: left;">6</td><td style="text-align: left;">667</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Sore throat</td><td style="text-align: left;"><p>12.3</p><p>(7.8‐17)</p></td><td style="text-align: left;">6</td><td style="text-align: left;">1429</td><td style="text-align: left;"><p>17</p><p>(14‐21)</p></td><td style="text-align: left;">20</td><td style="text-align: left;">2452</td><td style="text-align: left;"><p>16.5</p><p>(10‐26)</p></td><td style="text-align: left;">12</td><td style="text-align: left;">992</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Headache</td><td style="text-align: left;"><p>12.2</p><p>(8.3‐18)</p></td><td style="text-align: left;">10</td><td style="text-align: left;">1815</td><td style="text-align: left;"><p>38</p><p>(30‐46)</p></td><td style="text-align: left;">20</td><td style="text-align: left;">2617</td><td style="text-align: left;"><p>15</p><p>(11‐20)</p></td><td style="text-align: left;">12</td><td style="text-align: left;">1170</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Diarrhea</td><td style="text-align: left;"><p>7.3</p><p>(4.6‐11.4)</p></td><td style="text-align: left;">11</td><td style="text-align: left;">1710</td><td style="text-align: left;"><p>24</p><p>(17.5‐31.5)</p></td><td style="text-align: left;">20</td><td style="text-align: left;">2452</td><td style="text-align: left;">17.3 (14.5‐20.5)</td><td style="text-align: left;">13</td><td style="text-align: left;">1017</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Rhinorrhea</td><td style="text-align: left;"><p>6</p><p>(3‐12)</p></td><td style="text-align: left;">3</td><td style="text-align: left;">129</td><td style="text-align: left;"><p>13</p><p>(8.5‐20)</p></td><td style="text-align: left;">6</td><td style="text-align: left;">840</td><td style="text-align: left;">6 (1‐20)</td><td style="text-align: left;">6</td><td style="text-align: left;">479</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Nausea and vomiting</td><td style="text-align: left;"><p>6</p><p>(2.7‐13)</p></td><td style="text-align: left;">4</td><td style="text-align: left;">1387</td><td style="text-align: left;"><p>18.5</p><p>(13‐25</p></td><td style="text-align: left;">14</td><td style="text-align: left;">2410</td><td style="text-align: left;"><p>20</p><p>(16‐25)</p></td><td style="text-align: left;">12</td><td style="text-align: left;">863</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Runny nose</td><td style="text-align: left;"><p>4</p><p>(1‐14)</p></td><td style="text-align: left;">1</td><td style="text-align: left;">51</td><td style="text-align: left;"><p>18</p><p>(9‐30)</p></td><td style="text-align: left;">6</td><td style="text-align: left;">870</td><td style="text-align: left;"><p>21</p><p>(4‐61)</p></td><td style="text-align: left;">5</td><td style="text-align: left;">246</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;"><strong>Comorbid conditions</strong></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;"></td><td style="text-align: left;"><strong>COVID‐19</strong></td><td style="text-align: left;"><strong>SARS</strong></td><td style="text-align: left;"><strong>MERS</strong></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;"></td><td style="text-align: left;"><strong>Clinical presentation</strong> <a href="#rmv2112-note-0004" data-ref-type="fn"><sup>a</sup></a> <strong>(CI 95%)</strong></td><td style="text-align: left;"><strong>Included studies number</strong></td><td style="text-align: left;"><strong>Included patients number</strong></td><td style="text-align: left;"><strong>Clinical presentation</strong> <a href="#rmv2112-note-0004" data-ref-type="fn"><sup>a</sup></a> <strong>(CI 95%)</strong></td><td style="text-align: left;"><strong>Included studies number</strong></td><td style="text-align: left;"><strong>Included patients number</strong></td><td style="text-align: left;"><strong>Clinical Presentation</strong> <a href="#rmv2112-note-0004" data-ref-type="fn"><sup>a</sup></a> <strong>(CI 95%)</strong></td><td style="text-align: left;"><strong>Included studies number</strong></td><td style="text-align: left;"><strong>Included patients number</strong></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Recent travel or contact with endemic people resident of Wuhan</td><td style="text-align: left;"><p>69.5</p><p>(54.5‐81)</p></td><td style="text-align: left;">7</td><td style="text-align: left;">45 443</td><td style="text-align: left;"><p>26.5</p><p>(20‐34)</p></td><td style="text-align: left;">1</td><td style="text-align: left;">156</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Chronic diseases</td><td style="text-align: left;"><p>41.2</p><p>(20‐66)</p></td><td style="text-align: left;">3</td><td style="text-align: left;">1227</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Exposure to seafood market</td><td style="text-align: left;"><p>24.3</p><p>(9.6‐49)</p></td><td style="text-align: left;">5</td><td style="text-align: left;">732</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Sick contacts with respiratory illness</td><td style="text-align: left;"><p>15</p><p>(4.5‐39.6)</p></td><td style="text-align: left;">4</td><td style="text-align: left;">829</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Hypertension</td><td style="text-align: left;"><p>15</p><p>(8.5‐24.6)</p></td><td style="text-align: left;">10</td><td style="text-align: left;">46 270</td><td style="text-align: left;"><p>14</p><p>(5.5‐31)</p></td><td style="text-align: left;">4</td><td style="text-align: left;">504</td><td style="text-align: left;"><p>36</p><p>(28‐45)</p></td><td style="text-align: left;">10</td><td style="text-align: left;">677</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">ARDS</td><td style="text-align: left;"><p>10.6</p><p>(4‐26.7)</p></td><td style="text-align: left;">5</td><td style="text-align: left;">1439</td><td style="text-align: left;"><p>51</p><p>(6‐94)</p></td><td style="text-align: left;">2</td><td style="text-align: left;">204</td><td style="text-align: left;"><p>29</p><p>(14‐51)</p></td><td style="text-align: left;">2</td><td style="text-align: left;">55</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Diabetes</td><td style="text-align: left;"><p>8</p><p>(4‐15)</p></td><td style="text-align: left;">8</td><td style="text-align: left;">46 232</td><td style="text-align: left;"><p>9.9</p><p>(5‐16.5)</p></td><td style="text-align: left;">10</td><td style="text-align: left;">2304</td><td style="text-align: left;"><p>46</p><p>(34.5‐58)</p></td><td style="text-align: left;">17</td><td style="text-align: left;">1086</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Current smoker</td><td style="text-align: left;"><p>7.7</p><p>(3.7‐15)</p></td><td style="text-align: left;">5</td><td style="text-align: left;">1348</td><td style="text-align: left;"><p>7.5</p><p>(5‐11)</p></td><td style="text-align: left;">4</td><td style="text-align: left;">347</td><td style="text-align: left;"><p>21.5</p><p>(14‐32)</p></td><td style="text-align: left;">9</td><td style="text-align: left;">144</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Chronic liver disease</td><td style="text-align: left;"><p>5.7</p><p>(3.8‐8.4)</p></td><td style="text-align: left;">8</td><td style="text-align: left;">499</td><td style="text-align: left;"><p>13.5</p><p>(5‐30)</p></td><td style="text-align: left;">6</td><td style="text-align: left;">604</td><td style="text-align: left;"><p>9</p><p>(4‐21)</p></td><td style="text-align: left;">5</td><td style="text-align: left;">53</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Digestive system disease</td><td style="text-align: left;"><p>3.5</p><p>(2.5‐4.9)</p></td><td style="text-align: left;">2</td><td style="text-align: left;">1198</td><td style="text-align: left;"><p>10.5</p><p>(6.5‐6)</p></td><td style="text-align: left;">5</td><td style="text-align: left;">504</td><td style="text-align: left;"><p>16.5</p><p>(10‐25)</p></td><td style="text-align: left;">11</td><td style="text-align: left;">152</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Health care worker</td><td style="text-align: left;"><p>3</p><p>(2‐4.6)</p></td><td style="text-align: left;">3</td><td style="text-align: left;">46 196</td><td style="text-align: left;"><p>28.5</p><p>(18‐43)</p></td><td style="text-align: left;">12</td><td style="text-align: left;">2328</td><td style="text-align: left;"><p>21</p><p>(17‐25.5)</p></td><td style="text-align: left;">20</td><td style="text-align: left;">1232</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Past smoker</td><td style="text-align: left;"><p>3</p><p>(1.1‐7.5)</p></td><td style="text-align: left;">2</td><td style="text-align: left;">1239</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;"></td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Cardiovascular and cerebrovascular diseases</td><td style="text-align: left;"><p>2.3</p><p>(2.2‐2.5)</p></td><td style="text-align: left;">8</td><td style="text-align: left;">46 302</td><td style="text-align: left;"><p>9.5</p><p>(5‐22)</p></td><td style="text-align: left;">8</td><td style="text-align: left;">1045</td><td style="text-align: left;"><p>20.5</p><p>(15‐27)</p></td><td style="text-align: left;">15</td><td style="text-align: left;">407</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Chronic respiratory disease</td><td style="text-align: left;"><p>2.2</p><p>(0.6‐8)</p></td><td style="text-align: left;">4</td><td style="text-align: left;">45 911</td><td style="text-align: left;"><p>30</p><p>(15‐50)</p></td><td style="text-align: left;">10</td><td style="text-align: left;">2224</td><td style="text-align: left;"><p>9</p><p>(6.5‐12</p></td><td style="text-align: left;">1</td><td style="text-align: left;">939</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Cancer</td><td style="text-align: left;"><p>1.7</p><p>(0.4‐7.4)</p></td><td style="text-align: left;">6</td><td style="text-align: left;">46 078</td><td style="text-align: left;"><p>1.3</p><p>(0.2‐10)</p></td><td style="text-align: left;">3</td><td style="text-align: left;">504</td><td style="text-align: left;"><p>12</p><p>(7‐20)</p></td><td style="text-align: left;">10</td><td style="text-align: left;">182</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Renal failure</td><td style="text-align: left;"><p>2.3</p><p>(1‐4)</p></td><td style="text-align: left;">7</td><td style="text-align: left;">2289</td><td style="text-align: left;"><p>4</p><p>(2.5‐7)</p></td><td style="text-align: left;">8</td><td style="text-align: left;">1103</td><td style="text-align: left;"><p>20.5</p><p>(14‐24.5)</p></td><td style="text-align: left;">15</td><td style="text-align: left;">366</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;"><p>Bacteria</p><p>co‐infection</p></td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;"><p>20</p><p>(12‐31)</p></td><td style="text-align: left;">3</td><td style="text-align: left;">281</td><td style="text-align: left;"><p>17.7</p><p>(6‐42)</p></td><td style="text-align: left;">4</td><td style="text-align: left;">21</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Camel exposure</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;"><p>20</p><p>(12‐32)</p></td><td style="text-align: left;">9</td><td style="text-align: left;">657</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;"><strong>Chest X‐ray and CT scan</strong></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;"></td><td style="text-align: left;"><strong>COVID‐19</strong></td><td style="text-align: left;"><strong>SARS</strong></td><td style="text-align: left;"><strong>MERS</strong></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;"></td><td style="text-align: left;"><strong>Clinical presentation</strong> <a href="#rmv2112-note-0004" data-ref-type="fn"><sup>a</sup></a> <strong>(CI 95%)</strong></td><td style="text-align: left;"><strong>Included studies number</strong></td><td style="text-align: left;"><strong>Included patients number</strong></td><td style="text-align: left;"><strong>Clinical presentation</strong> <a href="#rmv2112-note-0004" data-ref-type="fn"><sup>a</sup></a> <strong>(CI 95%)</strong></td><td style="text-align: left;"><strong>Included studies number</strong></td><td style="text-align: left;"><strong>Included Patients Number</strong></td><td style="text-align: left;"><strong>Clinical presentation</strong> <a href="#rmv2112-note-0004" data-ref-type="fn"><sup>a</sup></a> <strong>(CI 95%)</strong></td><td style="text-align: left;"><strong>Included studies number</strong></td><td style="text-align: left;"><strong>Included patients number</strong></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Abnormal chest X ray</td><td style="text-align: left;"><p>84</p><p>(78‐8.5)</p></td><td style="text-align: left;">12</td><td style="text-align: left;">1706</td><td style="text-align: left;"><p>86</p><p>(77‐92)</p></td><td style="text-align: left;">20</td><td style="text-align: left;">1209</td><td style="text-align: left;"><p>74.7</p><p>(56.5‐87)</p></td><td style="text-align: left;">10</td><td style="text-align: left;">258</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Bilateral involvement</td><td style="text-align: left;"><p>76.8</p><p>(62.5‐87)</p></td><td style="text-align: left;">12</td><td style="text-align: left;">46 270</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Consolidation</td><td style="text-align: left;"><p>75.5</p><p>(50.5‐91)</p></td><td style="text-align: left;">6</td><td style="text-align: left;">1378</td><td style="text-align: left;"><p>41.5</p><p>(11‐80)</p></td><td style="text-align: left;">2</td><td style="text-align: left;">78</td><td style="text-align: left;"><p>18</p><p>(10‐30)</p></td><td style="text-align: left;">1</td><td style="text-align: left;">10</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Ground‐glass opacity</td><td style="text-align: left;"><p>71</p><p>(40‐90)</p></td><td style="text-align: left;">12</td><td style="text-align: left;">46 270</td><td style="text-align: left;"><p>41</p><p>(14‐76</p></td><td style="text-align: left;">3</td><td style="text-align: left;">340</td><td style="text-align: left;"><p>65</p><p>(52‐77)</p></td><td style="text-align: left;">1</td><td style="text-align: left;">36</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Unilateral involvement of chest radiography</td><td style="text-align: left;"><p>16.5</p><p>(8.5‐29.5)</p></td><td style="text-align: left;">6</td><td style="text-align: left;">1378</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;"><strong>Outcome</strong></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;"></td><td style="text-align: left;"><strong>COVID‐19</strong></td><td style="text-align: left;"><strong>SARS</strong></td><td style="text-align: left;"><strong>MERS</strong></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;"></td><td style="text-align: left;"><strong>Clinical presentation</strong> <a href="#rmv2112-note-0004" data-ref-type="fn"><sup>a</sup></a> <strong>(CI 95%)</strong></td><td style="text-align: left;"><strong>Included studies number</strong></td><td style="text-align: left;"><strong>Included patients number</strong></td><td style="text-align: left;"><strong>Clinical presentation</strong> <a href="#rmv2112-note-0004" data-ref-type="fn"><sup>a</sup></a> <strong>(CI 95%)</strong></td><td style="text-align: left;"><strong>Included studies number</strong></td><td style="text-align: left;"><strong>Included patients number</strong></td><td style="text-align: left;"><strong>Clinical presentation</strong> <a href="#rmv2112-note-0004" data-ref-type="fn"><sup>a</sup></a> <strong>(CI 95%)</strong></td><td style="text-align: left;"><strong>Included studies number</strong></td><td style="text-align: left;"><strong>Included patients number</strong></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Hospitalized</td><td style="text-align: left;"><p>85.4 (%)</p><p>(68‐94)</p></td><td style="text-align: left;">3</td><td style="text-align: left;">1378</td><td style="text-align: left;"><p>33</p><p>(11‐66)</p></td><td style="text-align: left;">3</td><td style="text-align: left;">87</td><td style="text-align: left;"><p>8</p><p>(1‐40)</p></td><td style="text-align: left;">5</td><td style="text-align: left;">1400</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Discharged</td><td style="text-align: left;"><p>14 (%)</p><p>(5.55‐31.5)</p></td><td style="text-align: left;">3</td><td style="text-align: left;">1378</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;"><p>40</p><p>(28‐53)</p></td><td style="text-align: left;">7</td><td style="text-align: left;">1660</td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Critical condition/ICU</td><td style="text-align: left;"><p>20.6 (%)</p><p>(6.7‐48)</p></td><td style="text-align: left;">6</td><td style="text-align: left;">45 951</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Mortality</td><td style="text-align: left;"><p>5.6 (%)</p><p>(2.5‐12.5)</p></td><td style="text-align: left;">8</td><td style="text-align: left;">47 200</td><td style="text-align: left;"><p>13</p><p>(9‐17)</p></td><td style="text-align: left;">20</td><td style="text-align: left;">5501</td><td style="text-align: left;"><p>35</p><p>(31‐39)</p></td><td style="text-align: left;">32</td><td style="text-align: left;">6987</td><td style="text-align: left;"></td></tr></tbody></table>

Abbreviations: ARDS, acute respiratory distress syndrome; CI, confidence interval; CT scan, CT scan; ICU, intensive care unit.

Age is an exception, presented in mean age in years.

Shortness of breath was less common in Covid‐19 patients 17% (95% CI 9‐31.5, *P* \< .001), in comparison to SARS 32% (95% CI 20‐46, *P* \< .001), and MERS 51% (95% CI 41‐63, *P* \< .001). Likewise, chills were less common in Covid‐19 patients 17% (95% CI 6.5‐38, *P* \< .001), in comparison to SARS 57.5% (95% CI 50‐64, *P* \< .001), and MERS 41% (95% CI 16‐72, *P* \< .001).

A much smaller proportion of COVID‐19 patients had sore throat 12.3% (95% CI 7.8‐17, *P* \< .06), headache 12.2% (95% CI 8.3‐18, *P* \< .001), diarrhea 7.3% (95% CI 4.6‐11.4, *P* \< .001), rhinorrhea 6% (95% CI 3‐12, *P* \< .43), nausea and vomiting 6% (95% CI 2.7‐13, *P* \< .001), or runny nose 6% **(**95% CI 1‐14, *P* \< .001**)**. More detail information about demographics and clinical characterization of COVID‐19 (Table S3), SARS (Table S4), and MERS patients (Table S5) demonstrated in the supplementary material.

3.4. Risk factors and clinical characteristics of patients infected with COVID‐19 {#rmv2112-sec-0018}
---------------------------------------------------------------------------------

The greatest risk for COVID‐19 patients 69.5% (95% CI 54.5‐81, *P* \< .001) up to 28 February 2020, is a history of recent travel to Wuhan, contact with people from Wuhan, or were Wuhan residents, and 24.3% (95% CI 9.6‐49, *P* \< .001) had exposure at the seafood market(s). The most common comorbid chronic condition for COVID‐19 and SARS is hypertension, and for MERS diabetes, 46% (95% CI 34.5‐58, *P* \< .001). Overall, 41.2% (95% CI 20‐66, *P* \< .001) of COVID‐19 patients had a history of chronic diseases. Acute respiratory syndrome (ARDS) occurred more frequently in SARS 51% (95% CI 6‐94, *P* \< .001) compared to MERS 29% (95% CI 14‐51, *P* \< .001) and COVID‐19 10.6% (95% CI 4‐26.7, *P* \< .001). More detailed information about comorbid conditions of COVID‐19 (Table S6), SARS (Table S7), and MERS (Table S8) patients is demonstrated in the supplementary material.

3.5. Chest X‐ray and CT scan findings in patients infected with COVID‐19 {#rmv2112-sec-0019}
------------------------------------------------------------------------

Analysis showed that 84% (95% CI 78‐8.5, *P* \< .001) of COVID‐19 patients, 86% (95% 77‐92, *P* \< .001) of SARS patients, and 74.7% (95% 56.5‐87, *P* \< .001) of MERS patients had abnormal radiological findings on chest X‐ray and CT scans. The radiological abnormalities in COVID‐19 patients were bilateral involvement of chest X‐ray 76.8% (95% CI 62.5‐87, *P* \< .001), consolidation 75.5% (95% CI 50.5‐91, *P* \< .001), and ground‐glass opacity 71% (95% CI 40‐90, *P* \< .001) (Table [2](#rmv2112-tbl-0002){ref-type="table"}). More detailed information about chest X‐ray and CT scan findings of COVID‐19 (Table S9), SARS (Table S10), and MERS patients (Table S11) is demonstrated in the supplementary material.

3.6. Outcome {#rmv2112-sec-0020}
------------

Most COVID‐19 confirmed patients required hospitalization 85.4% (95% CI 68‐94, *P* \< .001) and 20.6% (95% CI 6.7‐48, *P* \< .001) were deemed to be in critical condition. The mortality rate of COVID‐19 confirmed cases was 5.6% (95% CI 2.5‐12.5, *P* \< .001), SARS 13% (95% 9‐17, *P* \< .001), and MERS 35% (95% CI 31‐39, *P* \< .001) (Figure [2](#rmv2112-fig-0002){ref-type="fig"} **)**.

![Forest plot of the meta‐analysis on **mortality** outcome in patients with confirmed COVID‐19 (upper left), SARS (upper right), and MERS (lower left)](RMV-9999-e2112-g002){#rmv2112-fig-0002}

3.7. Laboratory findings of patients infected with COVID‐19 {#rmv2112-sec-0021}
-----------------------------------------------------------

The laboratory findings showed that among a subset of patients 4.5% (2361/52 251) where data were available, thrombocytosis in COVID‐19 patients was 61% (95% CI 45‐72, *P* \< .001) which is more than double that of SARS at 41.5% (95% CI 35‐56.4, *P* \< .001) and MERS 30% (95% CI 22‐58, *P* \< .001) (Table [3](#rmv2112-tbl-0003){ref-type="table"}). The most SARS patients 71% (95% CI 62‐78, *P* \< .001) had decreased lymphocytes, and the most of MERS patients had decrease platelets 62% (95% 52‐74, *P* \< .001) in their laboratory findings (Table [3](#rmv2112-tbl-0003){ref-type="table"} **)**.

###### 

Laboratory features for confirmed patients with COVID‐19

<table><thead><tr class="header"><th style="text-align: left;"></th><th style="text-align: left;">Normal range</th><th style="text-align: left;">Mean (CI 95%)</th><th style="text-align: left;">Total patient number</th><th style="text-align: left;">Number of studies</th><th style="text-align: left;">Mean (CI 95%)</th><th style="text-align: left;">Total patient number</th><th style="text-align: left;">Number of studies</th><th style="text-align: left;">Mean (CI 95%)</th><th style="text-align: left;">Total patient number</th><th style="text-align: left;">Number of studies</th></tr></thead><tbody><tr class="odd"><td style="text-align: left;"><strong>Leucocytes (WBCs)</strong></td><td style="text-align: left;">3.5‐9.5</td><td style="text-align: left;"><p>5.55 (×10<sup>9</sup> per L)</p><p>(5.1‐5.9)</p></td><td style="text-align: left;">2361</td><td style="text-align: left;">11</td><td style="text-align: left;"><p>5.1 (×10<sup>9</sup> per L)</p><p>(3.3‐7)</p></td><td style="text-align: left;">367</td><td style="text-align: left;">8</td><td style="text-align: left;"><p>7.4 (×10<sup>9</sup> per L)</p><p>(6‐8.7)</p></td><td style="text-align: left;">280</td><td style="text-align: left;">5</td></tr><tr class="even"><td style="text-align: left;">Increased</td><td style="text-align: left;"></td><td style="text-align: left;">13.3 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">28 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">30 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Decreased</td><td style="text-align: left;"></td><td style="text-align: left;">26 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">32 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">41 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;"><strong>Neutrophils</strong></td><td style="text-align: left;">1.8‐6.3</td><td style="text-align: left;"><p>3.6 (×10<sup>9</sup> per L)</p><p>(3.1‐4.1)</p></td><td style="text-align: left;">412</td><td style="text-align: left;">8</td><td style="text-align: left;"><p>4.6</p><p>(4.6‐7.1)</p></td><td style="text-align: left;">614</td><td style="text-align: left;">5</td><td style="text-align: left;"><p>5.3</p><p>(5‐5.5)</p></td><td style="text-align: left;">150</td><td style="text-align: left;">2</td></tr><tr class="odd"><td style="text-align: left;">Increased</td><td style="text-align: left;"></td><td style="text-align: left;">‐</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">5 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">‐</td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;">Decreased</td><td style="text-align: left;"></td><td style="text-align: left;">‐</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">17.5 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">‐</td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;"><strong>Lymphocytes</strong></td><td style="text-align: left;">1.1‐3.2</td><td style="text-align: left;"><p>0.98 (×10<sup>9</sup> per L)</p><p>(0.9‐1.06)</p></td><td style="text-align: left;">2361</td><td style="text-align: left;">11</td><td style="text-align: left;"><p>0.74 (×10<sup>9</sup> per L)</p><p>(0.66‐0.816)</p></td><td style="text-align: left;">825</td><td style="text-align: left;">10</td><td style="text-align: left;">‐</td><td style="text-align: left;">210</td><td style="text-align: left;">4</td></tr><tr class="even"><td style="text-align: left;">Decreased</td><td style="text-align: left;"></td><td style="text-align: left;">62.5 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">71 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">50 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;"><strong>Platelets</strong></td><td style="text-align: left;">125‐350</td><td style="text-align: left;"><p>186.5 (×10<sup>9</sup> per L)</p><p>(167‐205)</p></td><td style="text-align: left;">2200</td><td style="text-align: left;">9</td><td style="text-align: left;"><p>179 (×10<sup>9</sup> per L)</p><p>(159‐199)</p></td><td style="text-align: left;">1912</td><td style="text-align: left;">5</td><td style="text-align: left;">‐</td><td style="text-align: left;">178</td><td style="text-align: left;">3</td></tr><tr class="even"><td style="text-align: left;">Decreased</td><td style="text-align: left;"></td><td style="text-align: left;">13 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">0.2 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">62 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="odd"><td style="text-align: left;">Increased</td><td style="text-align: left;"></td><td style="text-align: left;">61 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">41.5 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">30 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;"><strong>CRP</strong> <a href="#rmv2112-note-0006" data-ref-type="fn"><sup><strong>a</strong></sup></a></td><td style="text-align: left;">0‐0.5</td><td style="text-align: left;"><p>29.6 (mg/L)</p><p>(16.7‐42.5)</p></td><td style="text-align: left;">290</td><td style="text-align: left;">5</td><td style="text-align: left;"><p>22.8 (mg/L)</p><p>(22‐35)</p></td><td style="text-align: left;">256</td><td style="text-align: left;">2</td><td style="text-align: left;">‐</td><td style="text-align: left;">156</td><td style="text-align: left;">3</td></tr><tr class="odd"><td style="text-align: left;">Increased</td><td style="text-align: left;"></td><td style="text-align: left;">81 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">93 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;">45 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr class="even"><td style="text-align: left;"><strong>Hemoglobin</strong></td><td style="text-align: left;">130‐175</td><td style="text-align: left;"><p>119 (g/L)</p><p>(106‐132)</p></td><td style="text-align: left;">2062</td><td style="text-align: left;">8</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td></tr><tr class="odd"><td style="text-align: left;"><strong>ESR</strong> <a href="#rmv2112-note-0106" data-ref-type="fn"><sup><strong>b</strong></sup></a></td><td style="text-align: left;">0‐15</td><td style="text-align: left;"><p>42 (mm/h)</p><p>(46‐57)</p></td><td style="text-align: left;">120</td><td style="text-align: left;">2</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td></tr><tr class="even"><td style="text-align: left;"><p><strong>Albumi</strong></p><p>Decreased</p></td><td style="text-align: left;">40‐55</td><td style="text-align: left;"><p>36.8 (g/L)</p><p>(24.5‐46)</p><p>80%</p></td><td style="text-align: left;">120</td><td style="text-align: left;">2</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td></tr><tr class="odd"><td style="text-align: left;"><p><strong>Interleukin‐6</strong></p><p>Increased</p></td><td style="text-align: left;">0.0‐7</td><td style="text-align: left;"><p>7.9 (mg/mL)</p><p>(6.8‐8.6)</p><p>52%</p></td><td style="text-align: left;">99</td><td style="text-align: left;">2</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td></tr><tr class="even"><td style="text-align: left;"><strong>LDH</strong> <a href="#rmv2112-note-0107" data-ref-type="fn"><sup><strong>c</strong></sup></a></td><td style="text-align: left;">120‐250</td><td style="text-align: left;"><p>280</p><p>(268‐294)</p></td><td style="text-align: left;">1783</td><td style="text-align: left;">9</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td><td style="text-align: left;">‐</td></tr><tr class="odd"><td style="text-align: left;">Increased</td><td style="text-align: left;"></td><td style="text-align: left;">70.3 (%)</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr></tbody></table>

Abbreviations: CRP, C reaction protein; ESR, erythrocyte sedimentation rate; WBCs, white blood cells.

Increased or decreased refers to values above or below the normal range.

erythrocyte sedimentation rate.

Lactate dehydrogenase.

4. DISCUSSION {#rmv2112-sec-0022}
=============

Prior to 2002, coronaviruses were associated with mild respiratory illness, but with the emergence of SARS in 2002, MERS in 2012, and now in late 2019, COVID‐19, it is established that coronaviruses infections can be associated with severe respiratory disease. The virus is transmitted via respiratory droplets or infected inanimate objects, and with its rapid spread worldwide in just a few months, the WHO has officially declared the COVID 19 outbreak a pandemic.[^22^](#rmv2112-bib-0022){ref-type="ref"}, [^126^](#rmv2112-bib-0126){ref-type="ref"}

Our results show that fever and cough were the most common clinical symptoms in COVID‐19, SARS, and MERS. Among 52 251 patients with COVID‐19 infection, while fatigue, sputum production, and myalgia (muscle soreness) were the next most frequent clinical symptoms; diarrhea, rhinorrhea, nausea, and vomiting were less common. Within the 10 037 confirmed SARS patients, the next most frequent clinical manifestations were chills, myalgia, headache, and dyspnea. Moreover, 8139 MERS patients commonly exhibited shortness of breath, chills, and dyspnea.

Shortness of breath was less common in COVID‐19 patients (17%), in comparison to SARS (32%) and MERS (51%). Likewise, chills were less common in COVID‐19 patients (17%), in comparison to SARS (57.5%) and MERS (41%). Therefore, these clinical symptoms should help distinguish the various coronavirus infections from each other.

Our analysis indicated recent travel to Wuhan, contact with people from Wuhan or residency in Wuhan, exposure to persons with respiratory symptoms, and seafood market exposures were common risks among those contracting COVID‐19. Furthermore, chronic respiratory disease and recent travel to SARS endemic areas were most common among those contracting SARS. In addition, 28% of SARS patients and 21% of MERS confirmed patients were health care workers, which is higher than COVID‐19 cases (3%). This data indicate that in coronavirus outbreaks, isolating infected individuals is one of the most important ways of controlling transmission.

We find that most of the patients with COVID‐19, SARS, and MERS had abnormal chest radiological findings. With ground‐glass opacity and consolidation in COVID‐19 patients being more frequent than in SARS and MERS patients. Other studies reported that significant similarity exists when comparing radiological findings of COVID‐19 patients with those suffering from complicated viral pneumonia such as SARS and MERS.[^22^](#rmv2112-bib-0022){ref-type="ref"}, [^32^](#rmv2112-bib-0032){ref-type="ref"} Therefore, there appear to be no distinguishing radiological findings when comparing human coronaviruses.

The mortality rate was 5.6%, 13%, and 35% among COVID‐19‐, SARS‐, and MERS‐infected patients, respectively. While the mortality rate among COVID‐19 patients is lower than SARS and MERS, COVID‐19 is proving to have a higher contagious potency, resulting in a higher number of deaths. It should be recognized that these numbers are biased due to the data set, including publications related to screening practices (eg, only those with symptoms being screened) increased the percentage value. The actual mortality rate from COVID‐19 is almost certainly much lower than that found in this study. As more data emerges from screening asymptomatic or mildly symptomatic individuals in China and around the world, the exact mortality rate will be better understood.

Among COVID‐19, SARS, and MERS patients, leukocytosis was found in 13.3%, 28%, and 30%, respectively, and leukopenia in 26%, 32%, and 41%, respectively.

Most of the patients with coronavirus had abnormal chest radiological findings. On the other hand, runny nose and rhinorrhea are less common symptoms in coronavirus‐infected patients,[^127^](#rmv2112-bib-0127){ref-type="ref"} which indicates the virus preferentially affects the lower respiratory tract. A study by Zhao et al showed that ACE2 is a COVID‐19 virus receptor and that it is typically expressed on pulmonary alveolar epithelial cells.[^128^](#rmv2112-bib-0128){ref-type="ref"} Another study reported that following COVID‐19 infection deregulated cytokine/chemokine response and higher virus titer causes an inflammatory cytokine storm with lung immunopathological injury.[^129^](#rmv2112-bib-0129){ref-type="ref"} Inflammation related to the cytokine storm in the lungs may then spread throughout the body via the circulation system. COVID‐19 patients have been reported to have increased plasma concentration of inflammation‐related cytokines, including interleukin (IL)‐2,6,7,10, tumor necrosis factor‐α (TNF‐α), and monocyte chemoattractant protein I (MCP‐I) especially in moribund patients.[^130^](#rmv2112-bib-0130){ref-type="ref"} Our data collected here show that ARDS occurred in 10.6% of reported patients with COVID‐19 infection. A previous study showed that ACE2 (main receptor of COVID‐19) expression is higher in people with pulmonary ARDS and acute respiratory injury.[^131^](#rmv2112-bib-0131){ref-type="ref"}

Several limitations of this study exist. Publication bias and study heterogeneity are unavoidable in this type of study. Therefore, it should be considered when interpreting the outcomes of the reports and our final data set. Furthermore, this study likely overestimates disease severity due to a lack of screening for asymptomatic or mildly symptomatic individuals and subsequent publication bias related to these factors. Likely, many infected persons have not been detected, thus falsely elevating the rates of hospitalization, critical condition, and mortality. The lower quality analysis and reporting in some of the included publications is another limitation of the study. To prevent language bias, we included reports in languages other than English. Additionally, we searched for a variety of sites and databases to prevent internet platform bias. Using Egger\'s regression test, we did not find significant publication bias. Journal bias is an issue facing those who carry out a meta‐analysis, yet it does not usually affect the general conclusions.[^132^](#rmv2112-bib-0132){ref-type="ref"} However, we cannot reject the occurrence of other biases in this study, such as choice bias, since several journals are not indexed in Embase, Scopus, PubMed, Web of Science, and the Cochrane library and unpublished data from some regions of the world.

5. CONCLUSIONS {#rmv2112-sec-0023}
==============

Fever and cough are the most common symptoms of COVID‐19‐, SARS‐, and MERS‐infected patients. The mortality rate in COVID‐19 confirmed cases was lower than SARS‐ and MERS‐infected patients. Clinical outcomes and findings may be biased by reporting only confirmed cases, and it should be considered when interpreting the data.
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